These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 10160494)

  • 1. Economic evaluation of vaccination.
    Van Damme P; Beutels P
    Pharmacoeconomics; 1996; 9 Suppl 3():8-15; discussion 23-5. PubMed ID: 10160494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A full economic evaluation of extensive vaccination against rotavirus with RIX4414 vaccine at National and Regional level in Italy].
    Vitale F; Barbieri M; Dirodi B; Vitali Rosati G; Franco E
    Ann Ig; 2013; 25(1):43-56. PubMed ID: 23435779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic evaluation of childhood 7-valent pneumococcal conjugate vaccination in Korea.
    Sohn HS; Suh DC; Jang E; Kwon JW
    J Manag Care Pharm; 2010; 16(1):32-45. PubMed ID: 20044845
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost effectiveness of adding 7-valent pneumococcal conjugate (PCV-7) vaccine to the Norwegian childhood vaccination program.
    Wisløff T; Abrahamsen TG; Bergsaker MA; Løvoll Ø; Møller P; Pedersen MK; Kristiansen IS
    Vaccine; 2006 Jul; 24(29-30):5690-9. PubMed ID: 16735083
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rethinking the benefits and costs of childhood vaccination: the example of the Haemophilus influenzae type b vaccine.
    Bärnighausen T; Bloom DE; Canning D; Friedman A; Levine OS; O'Brien J; Privor-Dumm L; Walker D
    Vaccine; 2011 Mar; 29(13):2371-80. PubMed ID: 21159324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
    Armstrong EP
    J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Economic evaluation of influenza vaccination. Assessment for The Netherlands.
    Postma MJ; Bos JM; van Gennep M; Jager JC; Baltussen R; Sprenger MJ
    Pharmacoeconomics; 1999; 16 Suppl 1():33-40. PubMed ID: 10623374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-benefit analysis of Haemophilus influenzae type b vaccination in children in Spain.
    Jiménez FJ; Guallar-Castillón P; Rubio Terrés C; Guallar E
    Pharmacoeconomics; 1999 Jan; 15(1):75-83. PubMed ID: 10345159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic Evaluation of Immunisation Programme of 23-Valent Pneumococcal Polysaccharide Vaccine and the Inclusion of 13-Valent Pneumococcal Conjugate Vaccine in the List for Single-Dose Subsidy to the Elderly in Japan.
    Hoshi SL; Kondo M; Okubo I
    PLoS One; 2015; 10(10):e0139140. PubMed ID: 26444287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination vaccine against invasive meningococcal B and pneumococcal infections: potential epidemiological and economic impact in the Netherlands.
    Bos JM; Rümke HC; Welte R; Spanjaard L; van Alphen L; Postma MJ
    Pharmacoeconomics; 2006; 24(2):141-53. PubMed ID: 16460135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness analysis of pneumococcal vaccination of adults and elderly persons in Belgium.
    De Graeve D; Lombaert G; Goossens H
    Pharmacoeconomics; 2000 Jun; 17(6):591-601. PubMed ID: 10977396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of childhood rotavirus vaccination in Germany.
    Aidelsburger P; Grabein K; Böhm K; Dietl M; Wasem J; Koch J; Ultsch B; Weidemann F; Wichmann O
    Vaccine; 2014 Apr; 32(17):1964-74. PubMed ID: 24561052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Budget impact analysis of vaccination against Haemophilus influenzae type b as a part of a Pentavalent vaccine in the childhood immunization schedule of Iran.
    Teimouri F; Kebriaeezadeh A; Zahraei SM; Gheiratian M; Nikfar S
    Daru; 2017 Jan; 25(1):1. PubMed ID: 28088246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic evaluation of Haemophilus influenzae type b vaccination in Moscow, Russian Federation.
    Platonov AE; Griffiths UK; Voeykova MV; Platonova OV; Shakhanina IL; Chistyakova GG; Robertson SE;
    Vaccine; 2006 Mar; 24(13):2367-76. PubMed ID: 16413949
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The burden of Haemophilus influenzae type b disease in Australia and an economic appraisal of the vaccine PRP-OMP.
    Harris A; Hendrie D; Bower C; Payne J; de Klerk N; Stanley F
    Med J Aust; 1994 Apr; 160(8):483-8. PubMed ID: 8170423
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Health economic evaluation of immunization strategies of hepatitis E vaccine for elderly population.
    Cheng X; Zhao Y; Zhang X; Jin H; Min J
    Hum Vaccin Immunother; 2017 Aug; 13(8):1873-1878. PubMed ID: 28448739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analysis of pneumococcal vaccination for elderly individuals in The Netherlands.
    Postma MJ; Heijnen ML; Jager JC
    Pharmacoeconomics; 2001; 19(2):215-22. PubMed ID: 11284385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of universal 7-valent pneumococcal conjugate vaccination in Taiwan: a cost-effectiveness analysis.
    Wu DB; Rinaldi F; Huang YC; Chang JA; Chang CJ
    J Formos Med Assoc; 2013 Mar; 112(3):151-60. PubMed ID: 23473528
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Health economic research on vaccinations and immunisation practices--an introductory primer.
    Szucs TD
    Vaccine; 2005 Mar; 23(17-18):2095-103. PubMed ID: 15755578
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of pneumococcal conjugate vaccination in Croatia.
    Vučina VV; Filipović SK; Kožnjak N; Stamenić V; Clark AD; Mounaud B; Blau J; Hoestlandt C; Kaić B
    Vaccine; 2015 May; 33 Suppl 1():A209-18. PubMed ID: 25919163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.